News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immuron.
RELATED STOCKHEAD STORIES
News
ASX Small Caps and IPO Weekly Wrap: Gold and medicine are the best medicine
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX dragged down by ex-divvy stocks as banks take lead; Gold’s rally relentless
News
ASX Small Caps Lunch Wrap: Which old timey space adventurer is on its last legs this week?
Health & Biotech
ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3
Health & Biotech
ASX Health Stocks: Immuron reports record sales for its diarrhoea drug, Travelan
Health & Biotech
ASX Health Stocks: Immuron chalks up record half for travelers’ diarrhoea medicine, Travelan
News
Closing Bell: Local markets ignore the conflict, follow the money to a fifth day of wins
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
Health & Biotech
ASX Health Stocks: Cann’s cannabis flower sales grow 500pc; Immuron runs out of Travelan as travel rebounds
Health & Biotech
The Ethical Investor: Why Starpharma and these ASX biotechs could stop the next infectious disease outbreak
News
CLOSING BELL: ASX closed 0.11% lower, because there was no one around last night to tell us what to do
Health & Biotech
ASX biotechs are looking up, and the FDA breakthroughs are starting to flow
Health & Biotech
ASX Health Stocks: Little Green Pharma gets French deal extension; FDA approves Immuron trial
Health & Biotech
ASX Health Stocks: Noxopharm plunges 45pc after discontinuing Veyonda clinical trials
News
Top 10 at 10: Western Mines up 315% in two days as good news keeps flowing
News